A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors

This study is testing a new, experimental pill called PLX-61639 to see if it can safely help treat certain advanced cancers that have a specific SMARCA4 gene mutation. Because these cancers have stopped responding to standard treatments, researchers are exploring this new approach to stop tumor growth.

You may be eligible if you have an advanced or spreading solid tumor (like certain lung, stomach, or esophageal cancers) that has a specific SMARCA4 genetic change. Participants must also be active enough to perform daily tasks and have healthy organ function as confirmed by their doctors.

After a screening process to confirm eligibility, you will take the study pill by mouth once every day in 28-day cycles. You will visit the research center regularly for check-ups and scans to monitor your health and how your tumor is responding to the treatment.

This study is currently recruiting patients at specific medical centers in Scottsdale, Arizona, and Duarte and Orange, California. You should speak with your oncologist to see if your specific cancer type qualifies for this trial.